Phase 2B Double Blind, Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to confirm the safety and pharmacological characteristics of
SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the
appropriate dose regimen for future studies in adult subjects with gout, with or without
tophi, and hyperuricemia refractory to SoC XOI therapy.